Table 1.
Baseline patient and treatment characteristics
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | |
|---|---|---|---|---|---|---|
| Sex | F | M | M | M | M | F |
| Tumor entity | Breast (adenocarcinoma) | Prostate (adenocarcinoma) | Rectum (adenocarcinoma) | Rectum (adenocarcinoma) | Primary: lung (small cell neuroendocrine); secondary: liver + bone (left shoulder) |
Rectum (adenocarcinoma) |
| Tumor stage | IA | IV | IIA | IIIB | IV | IIIA |
| Age (years) | 50 | 74 | 54 | 74 | 70 | 40 |
| Height (m) | 1.77 | 1.70 | 1.82 | 1.72 | 1.76 | 1.65 |
| Baseline weight (kg) | 88.9 | 67.5 | 76.4 | 89.4 | 114.0 | 55.9 |
| Main reasons for KD | Anticipated fat mass reduction; anti-cancer effects |
Anticipated body weight preservation | Anticipated anti-cancer effects | Anticipated anti-cancer effects; patient refusal of surgery | Anticipated anti-cancer effects; possibility to take action by oneself | Anticipated anti-cancer effects |
The overall tumor staging refers to the AJCC 7th edition